DNB Carnegie Lowers Price Target for Genmab to 1,985 Danish Kroner (from 2,050), Reiterates Hold
DNB Carnegie has lowered its price target for Genmab to 1,985 Danish kroner (previously 2,050), while reiterating its hold recommendation.
Source: marketscreener The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments